A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5050 participants.

Also called NCT02861534

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 5,050 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02861534
  • EudraCT 2016-000671-25
Other papers using this trial's data
  • Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial Circulation. Heart failure, 2023-09 DOI, PubMed 37417824
  • Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial European journal of heart failure, 2019-12 DOI, PubMed 31820546
  • Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial Journal of cardiac failure, 2023-08 DOI, PubMed 37331690, PMC10697691 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial JAMA cardiology, 2021-06-01 DOI, PubMed 33185650, PMC7666431 PubMed links an erratum for this paper. Erratum: PMID 33439227; Erratum: PMID 33787825; Erratum: PMID 34613337 Not in the PMC Open Access subset.
  • Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial Circulation, 2023-10-03 DOI, PubMed 37671551
  • Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial European journal of heart failure, 2022-09 DOI, PubMed 35791083
  • Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction JACC. Heart failure, 2024-05 DOI, PubMed 38363272
  • Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat JACC. Heart failure, 2022-09 DOI, PubMed 36049817
  • Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial JACC. Heart failure, 2024-10 DOI, PubMed 38934967
  • Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction The New England journal of medicine, 2020-05-14 DOI, PubMed 32222134

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02861534. Randomized; double masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2019-06-18 (actual). Results posted on 2020-06-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
Acronym
VICTORIA
Condition
Heart Failure
Intervention (Drug)
Vericiguat
Intervention (Drug)
Placebo for vericiguat
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Bayer (class: industry)
Collaborator
Canadian VIGOUR Centre (class: other)
Collaborator
Duke Clinical Research Institute (class: other)

Record details

Record id
cardio:ct-nct02861534
Content hash
6e52b794b563815c8b3f51c2c6f78f14e129cdf520ae48fd13d812c85a90c787